Related Experiment Video
Updated: Sep 11, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6
Hideaki Ishikawa1, Naohiro Tsuyama, Saeid Abroun
1Department of Bio-Signal Analysis, Applied Medical Engineering Science, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan.
Abstract:
Specific intracellular signals mediated by interleukin-6 (IL-6) receptor complexes, such as signal transducer and activator of transcription 3 (STAT 3) and extracellular signal-regulated kinase (ERK) 1/2, are considered to be responsible for inducing a variety of cellular responses. In multiple myeloma, IL-6 only enhanced the proliferation of CD45+ tumor cells that harbored the IL-6-independent activation of src family kinases even though STAT3 and ERK1/2 could be activated in response to IL-6 in both CD45+ and CD45(minus sign) cells. Furthermore, the IL-6-induced proliferation of CD45+ U266 myeloma cells was significantly suppressed by Lyn-specific antisense oligodeoxynucleotides or a selective src kinase inhibitor. These results indicate that the activation of both STAT3 and ERK1/2 is not enough for IL-6-induced proliferation of myeloma cell lines that require src family kinase activation independent of IL-6 stimulation. Thus, the activation of the src family kinases associated with CD45 expression is a prerequisite for the proliferation of myeloma cell lines by IL-6. We propose a mechanism for IL-6-induced cell proliferation that is strictly dependent upon the cellular context in myelomas.
Insights
Interleukin-6 (IL-6) promotes multiple myeloma cell proliferation only when src family kinases are activated independently of IL-6. This src family kinase activation, linked to CD45 expression, is essential for IL-6-driven myeloma cell growth.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Interleukin-6 (IL-6) signaling pathways, including STAT3 and ERK1/2, are crucial for cellular responses.
- Multiple myeloma is characterized by the dysregulation of cell proliferation pathways.
Purpose of the Study:
- To investigate the specific intracellular signals and cellular context required for IL-6-induced proliferation in multiple myeloma.
- To elucidate the role of src family kinases and CD45 expression in IL-6-mediated myeloma cell growth.
Main Methods:
- Activation of STAT3 and ERK1/2 pathways in response to IL-6.
- Assessment of IL-6 effects on CD45+ and CD45- myeloma cells.
- Inhibition of src family kinases using antisense oligodeoxynucleotides and selective inhibitors.
Main Results:
- IL-6 enhanced proliferation only in CD45+ myeloma cells with pre-existing IL-6-independent src family kinase activation.
- STAT3 and ERK1/2 activation by IL-6 occurred in both CD45+ and CD45- cells.
- Suppression of IL-6-induced proliferation in CD45+ U266 cells using Lyn-specific antisense or src kinase inhibitors.
Conclusions:
- STAT3 and ERK1/2 activation alone are insufficient for IL-6-induced myeloma cell proliferation.
- Src family kinase activation, associated with CD45 expression, is a prerequisite for IL-6-driven myeloma cell proliferation.
- IL-6-induced proliferation in myeloma is highly dependent on the cellular context and specific signaling pathways.
Related Concept Videos
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Differentiation of Common Myeloid Progenitor Cells
The JAK-STAT Signaling Pathway

